ICON Public (NASDAQ:ICLR) Lowered to Hold at StockNews.com

StockNews.com cut shares of ICON Public (NASDAQ:ICLR) from a buy rating to a hold rating in a report issued on Thursday.

ICLR has been the subject of a number of other research reports. The Goldman Sachs Group started coverage on shares of ICON Public in a report on Thursday, June 6th. They set a buy rating and a $370.00 price target for the company. TD Cowen lifted their price target on ICON Public from $349.00 to $373.00 and gave the company a buy rating in a research note on Friday, May 31st. Barclays lowered their price target on ICON Public from $355.00 to $350.00 and set an overweight rating for the company in a report on Friday, July 26th. William Blair reaffirmed an outperform rating on shares of ICON Public in a research note on Friday, May 31st. Finally, Robert W. Baird reissued an outperform rating and set a $368.00 target price on shares of ICON Public in a research note on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, ICON Public presently has a consensus rating of Buy and a consensus target price of $351.60.

ICON Public Price Performance

ICON Public stock opened at $303.07 on Thursday. The firm has a market cap of $25.00 billion, a PE ratio of 36.87, a price-to-earnings-growth ratio of 1.29 and a beta of 1.22. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.31 and a quick ratio of 1.31. The stock’s fifty day moving average price is $317.00 and its two-hundred day moving average price is $317.95. ICON Public has a one year low of $221.20 and a one year high of $347.72.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.75 EPS for the quarter, topping analysts’ consensus estimates of $3.68 by $0.07. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The company had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.14 billion. During the same quarter last year, the business earned $2.96 earnings per share. ICON Public’s revenue was up 4.1% on a year-over-year basis. As a group, research analysts expect that ICON Public will post 14.54 EPS for the current fiscal year.

Hedge Funds Weigh In On ICON Public

A number of hedge funds have recently modified their holdings of the business. Livelsberger Financial Advisory acquired a new stake in ICON Public in the fourth quarter valued at $29,000. Riverview Trust Co acquired a new stake in shares of ICON Public in the first quarter valued at about $31,000. Ashton Thomas Private Wealth LLC bought a new position in shares of ICON Public during the second quarter worth about $54,000. GAMMA Investing LLC lifted its stake in shares of ICON Public by 22.5% in the first quarter. GAMMA Investing LLC now owns 174 shares of the medical research company’s stock worth $58,000 after acquiring an additional 32 shares during the period. Finally, ORG Partners LLC bought a new stake in ICON Public in the second quarter valued at approximately $59,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.